Clinical Trials
AUS-NET – Neuroendocrine Tumours
To improve patient quality of life and develop a cost-effective system that can be implemented across other rare cancers in the future.
Clinical Trials
Trials posted here are for informational purposes only.
NeuroEndocrine Cancer Australia does not endorse any particular research study and is not responsible for the accuracy of the information provided by the investigator or the accuracy of the information provided by the searchable databases.
For further information see the Australian Governments Clinical Trials Website and Ancora’s Website.
Filter by:
Or browse by
popular tag:
Clinical Trials
Compose GEP-NET Phase III Trial
A phase III clinical trial investigating a new treatment option for advanced neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs)
Clinical Trials
ONJCRI Immunotherapy Trial: Nivolumab & Ipilimumab for Rare and Advanced Cancers
This protocol provides an important opportunity to establish whether the combination of nivolumab & ipilimumab has efficacy in these cancers.
Clinical Trials
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET)
PARLuNET is a phase 1 dose-escalation study designed to evaluate the safety and tolerability of talazoparib (PARP Inhibitor) in...
Clinical Trials
Phase 3 Trial of CAM2029 vs Standard Treatments in GEP-NET Patients
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET.
